Commercial FootprintKite has treated over 29,000+ patients with lymphoma at 550+ ATCs globally, creating an established footprint for a quicker launch for anito-cel.
Launch StrategyAnito-cel's very clean safety profile and class-leading efficacy should produce a highly differentiated CART launch, without limits seen by BMY's Abecma, and LEGN / JNJ's Carvykti.
Market OpportunityAnito-cel is expected to capture a significant portion of the $3.5 billion global CAR-T market opportunity in later lines of multiple myeloma therapy.